Here are the 10-K annual reports from Zomedica Corp (ZOMDF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZOMDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZOMDF filings page.
Zomedica Corp. files its annual report describing a much larger 2025 loss and a shift in its listing venue. The animal health company, which sells diagnostic and therapeutic devices for companion animals, reported a net loss of $81,786,000 versus $46,942,000 a year earlier and an accumulated deficit of $299,773,000. Total shareholders’ equity was $115,397,000, with 979,949,668 common shares outstanding and a non‑affiliate market value of about $38.3 million. After NYSE American suspended and delisted its shares on March 4, 2025 for prolonged low price, trading moved to the OTCQB under the symbol ZOMDF. Zomedica highlights six commercial product lines, ongoing R&D spending of $7.2 million, 141 employees, and extensive competition and risk factors, including supply chain disruption, regulatory changes, cybersecurity, and continued operating losses.